News Briefing channel feed

Gri­fols snags the rest of Gi­ga­Gen in $80M ac­qui­si­tion; Ver­tex moves cut­ting-edge di­a­betes treat­ment in­to the clin­ic

5 years ago

Mer­ck inks Keytru­da deal with Sur­face On­col­o­gy; Rock­et Phar­ma­ceu­ti­cals gets ex­pe­dit­ed re­view of gene ther­a­py for rare pe­di­atric dis­ease 

5 years ago

Mount Sinai leas­ing of­fice space for out­pa­tient clin­ics, biotech re­search; Zol­gens­ma OK to be sold in UK, NICE says

5 years ago

Seagen warns in­vestors against TRC Cap­i­tal’s lat­est 'mi­ni-ten­der of­fer'; BeiGene goes af­ter a new in­di­ca­tion for top PD-1 play­er

5 years ago

Gala­pa­gos posts a safe­ty win for fil­go­tinib, but is it too lit­tle, too late?; Bio-Techne inks $320M mol­e­c­u­lar di­ag­nos­tics buy­out

5 years ago

Presage teams with Mer­ck on its Phase 0 test­ing; Kem­Pharm AD­HD drug wins ap­proval in chil­dren aged 6 and up

5 years ago

Mesoblast gets a $110M life­line from Surg­Cen­ter De­vel­op­ment; uniQure still un­sure if gene ther­a­py spurred can­cer event

5 years ago

Mer­ck gets a PDU­FA date for its chron­ic cough con­tender; Mor­phic shares sky­rock­et on the heels of PhI da­ta roll­out in IBD

5 years ago

Gos­samer push­es ahead with failed asth­ma drug; Cull­gen gets $50M Se­ries B for pro­tein de­graders

5 years ago

Xen­cor, UCLA to part­ner for new ther­a­peu­tic an­ti­bod­ies; Schrödinger ex­pands part­ner­ship with Google Cloud

5 years ago

Ku­ra tees up its lead drug with a 'break­through' at the FDA; NCI teams up with Cy­brexa on pep­tide drug con­ju­gate

5 years ago

UCB builds on re­la­tion­ship with Mi­crosoft with new AI deal; Sanofi part­ners with Ger­man AAV vec­tor biotech

5 years ago

Am­gen lines up ex­pan­sion to Ote­zla's $13B fran­chise; Chi­na OKs 'break­through' use of PD-1

5 years ago

In­cyte scores speedy FDA re­view for JAK cream in atopic der­mati­tis; Lil­ly backs $90M raise for Re­gor

5 years ago

Proven­tion Bio inks Chi­na deal for au­toim­mune pro­gram; Ky­owa Kirin re­leas­es pos­i­tive topline da­ta in atopic der­mati­tis

5 years ago

Pfiz­er chips in on $26M raise for rheuma­toid arthri­tis col­lab­o­ra­tor; Han­soh li­cens­es an an­ti-fun­gal for a mys­te­ri­ous in­fec­tion

5 years ago

Cel­lec­tis signs $760M mile­stone deal with NK up­start; Im­muno­core brings on As­traZeneca vet to shep­herd bis­pe­cif­ic launch plans

5 years ago

Mys­tery in­vestors back a new NASH ap­proach; GSK an­tibi­otics sale trig­gers lay­off fears

5 years ago

Ex­sci­en­tia to col­lab­o­rate with Ox­ford's Alzheimer's cen­ter; Dana-Far­ber en­lists Reper­toire for head and neck can­cer

5 years ago

Mi­rati and MD An­der­son team up on KRAS; Sanofi inks deal with a Har­vard spin­out for oral bi­o­log­ics

5 years ago

J&J's Er­lea­da/Zyti­ga com­bo hits PhI­II end­point — but what about OS?; Tar­go­v­ax los­es prostate can­cer part­ner af­ter en­roll­ment strug­gles

5 years ago

Jasper's cell ther­a­py con­di­tion­ing agent shows promise in small study; Vi­iV's Ruko­bia sees ap­proval in Eu­rope

5 years ago

Ra­mona Se­queira to be­come PhRMA's first fe­male chair; McK­in­sey reach­es near­ly $574 mil­lion set­tle­ment over in­volve­ment in opi­oid cri­sis

5 years ago

Mu­ta­bilis re­ceives CARB-X grant for 'night­mare bac­te­ri­a' treat­ment; Ab­Sci and Xyphos shake hands on dis­cov­ery deal

5 years ago
First page Previous page 32333435363738 Next page Last page
A service from the Financial Times